Genetown
Filter News
Found 79,959 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
Axcella is prioritizing its clinical development portfolio to focus on its investigative assets for COVID-19 and non-alcoholic steatohepatitis (NASH) after abrupt leadership resignations.
-
Pharma giant Merck announced it is expanding in both area and headcount with a new Cambridge, MA office. The company's plan is to add 160,000 square feet and 100 new employees.
-
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative Colitis
5/27/2022
AbbVie announced The Lancet published results from three pivotal Phase 3 clinical trials – U-ACHIEVE, U-ACCOMPLISH and U-ACHIEVE – evaluating upadacitinib in patients with moderately to severely active ulcerative colitis who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.
-
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's Disease
5/27/2022
AbbVie announced The Lancet published results from three pivotal Phase 3 clinical trials – ADVANCE, MOTIVATE and FORTIFY – evaluating risankizumab in patients with moderately to severely active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.
-
KalVista Pharmaceuticals Announces Changes to Board of Directors
5/27/2022
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced that Patrick A. Treanor has been appointed and Dan Soland is resigning from the Company’s Board of Directors.
-
Oak Hill Bio to Participate in 2022 Wells Fargo Private Biotech Symposium
5/27/2022
Oak Hill Bio (“Oak Hill”), a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases, today announced that members of its senior leadership team will participate in virtual one-on-one meetings with investors at the upcoming 2022 Wells Fargo Private Biotech Symposium.
-
Novel Assay for Early Detection of Ovarian Cancer From Mercy BioAnalytics Significantly Outperforms CA125 in New Research Presented at ASCO Annual Meeting
5/27/2022
Mercy Halo Data Demonstrates Promise of Novel Extracellular Vesicle Biomarker-Based Approach for Early Cancer Detection.
-
Elicio Therapeutics Presents Design of Ongoing AMPLIFY-201 Study in Mutant KRAS-Driven Cancers at ASCO Annual Meeting 2022
5/27/2022
Elicio Therapeutics today announced it is presenting a poster on the AMPLIFY-201 study design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, being held in-person from June 3-7, 2022, in Chicago.
-
Jacobio will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting
5/27/2022
Jacobio Pharma (1167.HK) is pleased to announce that the phase I clinical data of KRAS G12C inhibitor JAB-21822 will be presented in the form of poster at the upcoming 2022 annual meeting of American Society of Clinical Oncology (ASCO) from June 3, 2022 to June 7, 2022.
-
Allarity Therapeutics Reports First Quarter 2022 Financial Results
5/27/2022
Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today reported financial results for the first quarter ended March 31, 2022.
-
Flagship Pioneering introduced ProFound Therapeutics, a new company that leverages previously undiscovered human proteins to develop treatments for many diseases.
-
Mersana Therapeutics to Present at Upcoming Investor Conferences in June 2022
5/26/2022
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, announced that members of management will present at three upcoming investor conferences.
-
Syndax Announces Participation at Two Upcoming Investor Conferences in June 2022
5/26/2022
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that members of its management team will participate in two upcoming investor conferences.
-
Lyra Therapeutics to Present at Upcoming Investor Conferences - May 26, 2022
5/26/2022
Lyra Therapeutics, Inc. announced that Maria Palasis, Ph.D., Lyra's President and Chief Executive Officer, will present at two upcoming investor conferences.
-
Anthos Therapeutics Appoints Drew Young as Chief Commercial Officer and Head of Patient Experience
5/26/2022
Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced the appointment of Drew Young as Chief Commercial Officer and Head of Patient Experience.
-
Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer
5/26/2022
Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced the publication of abstract #9037 at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7, 2022, in Chicago.
-
OmniGuide Holdings Receives FDA Clearance for RevoLix™ HTL Hybrid Thulium Laser for the treatment of BPH and Stones
5/26/2022
OmniGuide Holdings (OGH) Today, the U.S. Food and Drug Administration cleared RevoLix™ HTL a family of pulsed and continuous wave Thulium YAG lasers is the foundation of RevoLix Therapy for urology patients undergoing BPH and Stone Management procedures.
-
Nexus Medical Labs Receives FDA Emergency Use Authorization for SARS-CoV-2 Test Using the RHINOstic™ Automated Nasal Swab from Rhinostics
5/26/2022
Rhinostics Inc. and Nexus Medical Labs recently received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a molecular SARS-CoV-2 test enabling unsupervised self-collection.
-
Q32 Bio Initiates First-in-Human Phase 1 Clinical Study of ADX-097 for the Treatment of Complement Disorders
5/26/2022
Q32 Bio , a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that dosing has been initiated in the healthy volunteer portion of its Phase 1, single ascending dose and multiple ascending dose (SAD/MAD) clinical study evaluating ADX-097, a first-in-class fusion protein, for the treatment of complement disorders.